{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:12:05Z","timestamp":1778249525871,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["ST-22"],"award-info":[{"award-number":["ST-22"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114681","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T07:39:53Z","timestamp":1680853193000},"page":"114681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic"],"prefix":"10.1016","volume":"162","author":[{"given":"Daria","family":"Schetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara Elizabeth","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Sein Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Wiergowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Koci\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10312","key":"10.1016\/j.biopha.2023.114681_bib1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2023.114681_bib2","first-page":"615","article-title":"Dynamics of the coronavirus disease 2019 outbreak in Poland: an epidemiological analysis of the first 2 months of the epidemic. Pol","volume":"130","author":"Raciborski","year":"2020","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2023.114681_bib3","unstructured":"A. Lipiec, Operacja w Czasie Epidemii Koronawirusa, a Kiedy nie mo\u017ce by\u0107 Odwo\u0142any? [Surgery during the Coronavirus Epidemic. When Should Procedures be Canceled, and When Can\u2019t They be Canceled?], 2020. Available online: \u3008https:\/\/www.medonet.pl\/koronawirus\/koronawirus-w-polsce,operacja-w-czasie-epidemii-koronawirusa--kiedy-zabieg-powinien--a-kiedy-nie-moze-byc-odwolany-,artykul,63135753.html\u3009, (Accessed 05 May 2022)."},{"issue":"22","key":"10.1016\/j.biopha.2023.114681_bib4","doi-asserted-by":"crossref","first-page":"8344","DOI":"10.3390\/ijerph17228344","article-title":"Self-medication-related behaviors and Poland's COVID-19 lockdown","volume":"17","author":"Makowska","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.biopha.2023.114681_bib5","doi-asserted-by":"crossref","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2023.114681_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2023.114681_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.biopha.2023.114681_bib8","doi-asserted-by":"crossref","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","volume":"369","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2023.114681_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2023.114681_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.biopha.2023.114681_bib11","article-title":"Safety and efficacy of fluvoxamine in COVID\u201019 ICU patients: an open label, prospective cohort trial with matched controls","author":"Calusic","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114681_bib12","doi-asserted-by":"crossref","unstructured":"Wei Zheng, He-Li Sun, Hong Cai, Qinge Zhang, Chee H. Ng, Yu-Tao Xiang, Antidepressants for COVID-19: a systematic review, J. Affect. Disord., vol. 307, 2022, pp. 108\u201314. ISSN 0165-0327. \u3008https:\/\/doi.org\/10.1016\/j.jad.2022.03.059\u3009.","DOI":"10.1016\/j.jad.2022.03.059"},{"issue":"1","key":"10.1016\/j.biopha.2023.114681_bib13","doi-asserted-by":"crossref","first-page":"1860356","DOI":"10.1080\/20008198.2020.1860356","article-title":"Adjustment disorder, traumatic stress, depression and anxiety in Poland during an early phase of the COVID-19 pandemic","volume":"12","author":"Dragan","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.biopha.2023.114681_bib14","unstructured":"First Confirmed Case of Novel Coronavirus in Australia, Australian Government Department of Health, 2020. Archived from the original on 15 February 2020. Retrieved 3 March 2020: \u3008https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/first-confirmed-case-of-novel-coronavirus-in-australia\u3009."},{"key":"10.1016\/j.biopha.2023.114681_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.5694\/mja2.50831","article-title":"Mental health of people in Australia in the first month of COVID-19 restrictions: a national survey","volume":"213","author":"Fisher","year":"2020","journal-title":"Med. J. Aust."},{"issue":"1","key":"10.1016\/j.biopha.2023.114681_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.12740\/APP\/115009","article-title":"Antidepressant use in Poland in the years 2010\u20132018","volume":"22","author":"Bli\u017aniewska-Kowalska","year":"2020","journal-title":"Arch. Psychiatry Psychother."},{"key":"10.1016\/j.biopha.2023.114681_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2020.102066","article-title":"COVID-19 and mental health: a review of the existing literature","volume":"52","author":"Rajkumar","year":"2020","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.biopha.2023.114681_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2021.08.153","article-title":"Mental health over nine months during the SARS-CoV2 pandemic: representative cross-sectional survey in twelve waves between April and December 2020 in Austria","volume":"296","author":"Niederkrotenthaler","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.biopha.2023.114681_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2022.154656","article-title":"Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: a review","volume":"829","author":"Diaz-Camal","year":"2022","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.biopha.2023.114681_bib20","unstructured":"K. Klinger, P. Otto-Duszczyk, Dziennik Gazeta Prawna, Tabletk\u0105 w stresogennego koronawirusa. Sprzeda\u017c lek\u00f3w antydepresyjnych i uspokajaj\u0105cych zwi\u0119kszy\u0142a si\u0119, 2020. \u3008https:\/\/serwisy.gazetaprawna.pl\/zdrowie\/artykuly\/1469668,koronawirus-sprzedaz-lekow-antydepresyjnych-uspokajajacych.html\u3009, (Accessed 12 March 2023)."},{"key":"10.1016\/j.biopha.2023.114681_bib21","series-title":"Health at a Glance","year":"2019"},{"key":"10.1016\/j.biopha.2023.114681_bib22","unstructured":"Australian Institute of Health and Welfare, Mental Health Services in Australia, 2021. Available at: \u3008www.aihw.gov.au\/reports\/mental-health-services\/mental-health-services-in-australia\/report-contents\/mental-health-related-prescriptions\/prescriptions\u3009, (Accessed 10 March 2023)."},{"key":"10.1016\/j.biopha.2023.114681_bib23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/pds.5093","article-title":"A national study on prescribed medicine use in Australia on a typical day","volume":"29","author":"Wylie","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.biopha.2023.114681_bib24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/00048670902970882","article-title":"2007 national survey of mental health and wellbeing: methods and key findings","volume":"43","author":"Slade","year":"2009","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.biopha.2023.114681_bib25","first-page":"1","article-title":"Antidepressant use among adults: United States, 2015\u20132018","volume":"377","author":"Brody","year":"2020","journal-title":"NCHS Data Briefs"},{"key":"10.1016\/j.biopha.2023.114681_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042696","article-title":"Sex and age differences in clinically significant symptoms of depression and anxiety among people in Australia in the first month of COVID-19 restrictions: a national survey","volume":"10","author":"Hammarberg","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2023.114681_bib27","unstructured":"Australian Institute of Health and Welfare. Mental Health Impact of COVID-19, 2021. Available at: \u3008www.aihw.gov.au\/reports\/mental-health-services\/mental-health-services-in-australia\u3009, (Accessed 10 March 2023)."},{"issue":"1","key":"10.1016\/j.biopha.2023.114681_bib28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/00048674221079740","article-title":"Changes in antidepressant use in Australia: a nationwide analysis (2015\u20132021)","volume":"57","author":"de Oliveira Costa","year":"2023","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.biopha.2023.114681_bib29","first-page":"14","article-title":"(red. nauk.): \u201cBezpiecze\u0144stwo farmakoterapii. Podr\u0119cznik pharmacovigilance\u201d","author":"Maciejczyk","year":"2017","journal-title":"Warszawa"},{"key":"10.1016\/j.biopha.2023.114681_bib30","series-title":"Half Yearly Performance Snapshot: July\u2013December 2019","year":"2020"},{"key":"10.1016\/j.biopha.2023.114681_bib31","doi-asserted-by":"crossref","unstructured":"Heba Ibrahim, A. Abdo, Ahmed M. El Kerdawy, A. Sharaf Eldin, Signal detection in pharmacovigilance: a review of informatics-driven approaches for the discovery of drug-drug interaction signals in different data sources, Artif. Intell. Life Sci., vol. 1, 2021, 100005. ISSN 2667-3185. \u3008https:\/\/doi.org\/10.1016\/j.ailsci.2021.100005\u3009. \u3008https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2667318521000052\u3009.","DOI":"10.1016\/j.ailsci.2021.100005"},{"issue":"10","key":"10.1016\/j.biopha.2023.114681_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241377","article-title":"Drug-safety reporting in Polish nursing practice-cross sectional surveys","volume":"15","author":"Zimmermann","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114681_bib33","first-page":"475","volume":"72","author":"Schetz","year":"2015"},{"key":"10.1016\/j.biopha.2023.114681_bib34","unstructured":"M.E. Wiktorowicz, J. Lexchin, M. Paterson, B. Mintzes, C. Metge, D. Light, et al., Research networks involved in post-market pharmacosurveillance in the United States, United Kingdom, France, New Zealand, Australia, Norway and European Union: lessons for Canada, Canadian Patient Safety Institute, Edmonton (AB), 2008. \u3008https:\/\/www.patientsafetyinstitute.ca\/en\/toolsResources\/Research\/commissionedResearch\/postMarketingSurveillance\/Pages\/researchResults.aspx\u3009, [cited 2021 Jan 4]."},{"key":"10.1016\/j.biopha.2023.114681_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.biopha.2023.114681_bib36","series-title":"Half Yearly Performance Snapshot: July\u2013December 2019","year":"2020"},{"key":"10.1016\/j.biopha.2023.114681_bib37","unstructured":"Najwy\u017csza Izba Kontroli, Delegatura w Poznaniu, Monitorowanie Niepo\u017c\u0105danych Dzia\u0142a\u0144 Lek\u00f3w, (\u3008https:\/\/www.nik.gov.pl\/plik\/id,23133,vp,25839.pdf\u3009), [cited 2021 Jan 4]."},{"issue":"10","key":"10.1016\/j.biopha.2023.114681_bib38","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00228-022-03372-5","article-title":"Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use","volume":"78","author":"Foletto","year":"2022","journal-title":"Eur. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114681_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221848","article-title":"Systematic review of patient and caregivers\u2019 satisfaction with telehealth videoconferencing as a mode of service delivery in managing patients\u2019 health","volume":"14","author":"Orlando","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.114681_bib40","unstructured":"OECD\/European Observatory on Health Systems and Policies, Country Health Profiles, 2021. Available online: \u3008https:\/\/www.oecd.org\/health\/country-health-profiles-eu.htm\u3009, (Accessed 10 March 2023)."},{"key":"10.1016\/j.biopha.2023.114681_bib41","unstructured":"Australian Department of Health, Telehealth services, 2021. Retrieved from \u3008https:\/\/www.health.gov.au\/initiatives-and-programs\/telehealth\/telehealth-services\u3009, (Accessed 11 March 2023)."},{"key":"10.1016\/j.biopha.2023.114681_bib42","unstructured":"Australian Bureau of Statistics, Household Impacts of COVID-19 Survey: November 2020, 2021. Retrieved from \u3008https:\/\/www.abs.gov.au\/statistics\/people\/people-and-communities\/household-impacts-covid-19-survey\/nov-2020\u3009, (10 March 2023)."},{"issue":"6","key":"10.1016\/j.biopha.2023.114681_bib43","first-page":"321","article-title":"The Australian response to the COVID-19 pandemic and implications for the future of telehealth worldwide","volume":"27","author":"Caffery","year":"2021","journal-title":"J. Telemed. Telecare"},{"issue":"4","key":"10.1016\/j.biopha.2023.114681_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2105\/AJPH.2020.306138","article-title":"The pandemic and the supply chain: gaps in pharmaceutical production and distribution","volume":"111","author":"Socal","year":"2021","journal-title":"Am. J. Public Health"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223004699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:22:12Z","timestamp":1778246532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223004699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":44,"alternative-id":["S0753332223004699"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114681","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reports analysis of psychotropic drugs related adverse reactions in Australia and Poland during the COVID 19 pandemic","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114681"}}